SHYNDEC's holding subsidiary signs the "Drug Marketing Authorization Transfer Agreement"
I'm PortAI, I can summarize articles.
SHYNDEC's subsidiary Guoyao Zhijun Ping Shan signed a "Drug Marketing Authorization Transfer Agreement" with Anhui Meilai, transferring the marketing authorization for Lactulose Oral Solution (15ml:10g) for a transfer fee of 5.86 million yuan. This move aims to enrich the company's product pipeline, enhance market competitiveness, and aligns with the company's medium to long-term development strategy. This matter has no significant impact on the company's current operating performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments